Where a 7% dividend yield hides a multitude of issues
Updates covered here include a trading update from an unusual provider of alternative finance solutions, which comes with the appeal of big dividend payments. We question the merits of its unusual business model. Read on for this and other news from AIM.
IXICO: another nice contract win for one of our Bonkers Bargains IXICO (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience and one of our Bonkers Bargain selections, announced that it has been selected by a leading European biopharmaceutical company to provide MRI and DAT-SPECT imaging services for a Phase 2 clinical trial in Parkinson's disease. You can read our Bonkers Bargain overage on this business here. This is the second study award with this client in the last twelve months, with the contract worth over £0.8m to IXI over a period of four and a half years. Giulio…